RESEARCH-USE BIOSIMILAR ANTIBODY

Ozanezumab

Monoclonal antibody · IgG1

RTN4IgG1RUO

Ozanezumab (GSK1223249) is a humanized, Fc-inactivated monoclonal antibody that targets the nervous system protein Nogo-A. Ozanezumab promotes neurite outgrowth and axonal regeneration by neutralizing Nogo-A signaling. Ozanezumab is used for research on neurodegenerative diseases such as amyotrophic lateral sclerosis and multiple sclerosis[1].

TARGETRTN4
YMonoclonal antibody
CATALOGSC-BS-301
CATALOG NUMBERSC-BS-301
MOLECULAR WEIGHTApprox. 145.227 kDa
PRODUCT FORMATMonoclonal antibody

A research-use configuration for comparative antibody studies

Ozanezumab (GSK1223249) is a humanized, Fc-inactivated monoclonal antibody that targets the nervous system protein Nogo-A. Ozanezumab promotes neurite outgrowth and axonal regeneration by neutralizing Nogo-A signaling. Ozanezumab is used for research on neurodegenerative diseases such as amyotrophic lateral sclerosis and multiple sclerosis[1].

Ozanezumab is a recombinant research-use antibody directed against RTN4.

START A CONVERSATION

Tell us about your research goals.

For quotes, sample requests or technical support, start with your target and experimental context.

Contact StellaCyte